Wnt Signaling Pathway and Chronic Myelogenous Leukemia

• Main Authors: HOU Yan, LI Wenqian, FENG Jianming, AI Guo, XIE Youbang, HUA Qingcuo, ZHAO Changming
• Format: Article
• Language: zho
• Published: Magazine House of Cancer Research on Prevention and Treatment 2019-02-01
• Series: Zhongliu Fangzhi Yanjiu
• Subjects: chronic myelogenous leukemia; wnt; leukemia stem cell; tki
• Online Access: http://html.rhhz.net/ZLFZYJ/html/8578.2019.18.0899.htm

As a type of cancer that starts in certain blood-forming cells of the bone marrow, chronic myeloid leukemia (CML) is caused by the formation of an abnormal gene called BCR-ABL1. The targeted medicine TKI for BCR-ABL1 has great effect on treating CML: however, TKI is not able to completely remove the leukemia stem cells (LSCs) in CML patients, which will lead to drug resistance and leukemia relapse. With the application of Wnt signaling pathway in regulating stem cell function, many studies have found that it also plays an important role in treating CML. In this paper, we reviewed the impact of Wnt signaling pathway on CML therapy.